# Mineralys Therapeutics, Inc. (MLYS) Stock Report: Navigating Biotech’s Potential with a 14.88% Upside

- Link: https://www.directorstalkinterviews.com/mineralys-therapeutics-inc-mlys-stock-report-navigating-biotechs-potential-with-a-14-88-upside/4121224400
- Published: 2025-11-04T11:46:42+00:00
- Author: Madison Wilson

Mineralys Therapeutics, Inc. (NASDAQ: MLYS) is making waves in the healthcare sector,
specifically within the biotechnology industry. With a current market cap of $3.04
billion, the company is focused on developing innovative treatments for diseases
driven by dysregulated aldosterone. At the forefront of its pipeline is lorundrostat,
a promising candidate targeting cardiorenal conditions such as hypertension and 
chronic kidney disease.

Currently priced at $39.17, MLYS has experienced a slight dip of 0.04% recently,
but this minor decline is overshadowed by its impressive 52-week range from a low
of $8.76 to a high of $44.16. This trajectory indicates a strong investor confidence
and growth potential, particularly evident in its average target price of $45.00,
which suggests a potential upside of 14.88%.

Despite the lack of traditional valuation metrics such as a trailing P/E ratio or
price-to-book ratio, which are not applicable due to the company’s clinical-stage
status, the forward P/E stands at -14.76. This reflects the high-risk, high-reward
nature often seen in biotech companies still in the developmental phase. Investors
should note that the company currently reports a negative EPS of -3.56 and a return
on equity of -63.21%, highlighting the financial challenges typical of firms in 
this sector.

Mineralys’s financials, including a free cash flow of -$122 million, underscore 
the capital-intensive nature of clinical trials and drug development. However, with
zero dividends or payout ratio, the company is clearly reinvesting in its growth
strategy, focusing on advancing lorundrostat through critical clinical trials.

The technical indicators paint an intriguing picture. The stock’s 50-day moving 
average is positioned at $36.63, while the 200-day moving average is significantly
lower at $19.22, suggesting a strong upward trend over the long term. The RSI of
44.86 indicates that the stock is neither overbought nor oversold, positioning it
neutrally in terms of momentum. The MACD of 1.01, alongside a signal line of 1.72,
further supports a cautiously optimistic outlook for technical traders.

Mineralys has garnered considerable attention from analysts, reflected in the eight
buy ratings and one hold rating, with no sell recommendations. This overwhelmingly
positive sentiment emphasizes the market’s belief in the company’s potential to 
achieve significant breakthroughs with lorundrostat, especially given its pivotal
program for uncontrolled or resistant hypertension.

For investors eyeing the biotechnology space, Mineralys Therapeutics presents a 
compelling opportunity. The company’s focus on addressing significant unmet medical
needs, combined with its robust clinical pipeline, makes it a noteworthy contender
in the race to develop next-generation therapies. As the company progresses through
its clinical trials, investors will be keenly watching for updates that could further
influence the stock’s trajectory and validate its promising 14.88% potential upside.

Share on:
